» Articles » PMID: 18926329

Long-term Outcome and Risk Stratification in Dilated Cardiolaminopathies

Abstract

Objectives: The aim of this study was to analyze the long-term follow-up of dilated cardiolaminopathies.

Background: Lamin A/C (LMNA) gene mutations cause a variety of phenotypes. In the cardiology setting, patients diagnosed with idiopathic dilated cardiomyopathy (DCM) plus atrioventricular block (AVB) constitute the majority of reported cases.

Methods: Longitudinal retrospective observational studies were conducted with 27 consecutive families in which LMNA gene defects were identified in the probands, all sharing the DCM phenotype.

Results: Of the 164 family members, 94 had LMNA gene mutations. Sixty of 94 (64%) were phenotypically affected whereas 34 were only genotypically affected, including 5 with pre-clinical signs. Of the 60 patients, 40 had DCM with AVB, 12 had DCM with ventricular tachycardia/fibrillation, 6 had DCM with AVB and Emery-Dreifuss muscular dystrophy type 2 (EDMD2), and 2 had AVB plus EDMD2. During a median of 57 months (interquartile range 36 to 107 months), we observed 49 events in 43 DCM patients (6 had a later event, excluded from the analysis). The events were related to heart failure (15 heart transplants, 1 death from end-stage heart failure) and ventricular arrhythmias (15 sudden cardiac deaths and 12 appropriate implantable cardioverter-defibrillator interventions). By multivariable analysis, New York Heart Association functional class III to IV and highly dynamic competitive sports for >or=10 years were independent predictors of total events. By a bivariable Cox model, splice site mutations and competitive sport predicted sudden cardiac death.

Conclusions: Dilated cardiomyopathies caused by LMNA gene defects are highly penetrant, adult onset, malignant diseases characterized by a high rate of heart failure and life-threatening arrhythmias, predicted by New York Heart Association functional class, competitive sport activity, and type of mutation.

Citing Articles

Genotype-phenotype insights of pediatric dilated cardiomyopathy.

Dai Y, Wang Y, Fan Y, Han B Front Pediatr. 2025; 13:1505830.

PMID: 39959410 PMC: 11825472. DOI: 10.3389/fped.2025.1505830.


Contemporary Insights into LMNA Cardiomyopathy.

Balakrishnan I, Lakdawala N Curr Cardiol Rep. 2025; 27(1):40.

PMID: 39869235 DOI: 10.1007/s11886-025-02195-x.


Dilated Cardiomyopathy: A Genetic Journey from Past to Future.

Newman N, Burke M Int J Mol Sci. 2024; 25(21).

PMID: 39519012 PMC: 11546582. DOI: 10.3390/ijms252111460.


Genetic and Pathophysiological Basis of Cardiac and Skeletal Muscle Laminopathies.

Bhide S, Chandran S, Rajasekaran N, Melkani G Genes (Basel). 2024; 15(8).

PMID: 39202453 PMC: 11354015. DOI: 10.3390/genes15081095.


Characterization and natural history of patients with LMNA-related dilated cardiomyopathy in the phase 3 REALM-DCM trial.

Garcia-Pavia P, Lakdawala N, Sinagra G, Ripoll-Vera T, Afshar K, Priori S ESC Heart Fail. 2024; 11(6):4201-4208.

PMID: 39145700 PMC: 11631308. DOI: 10.1002/ehf2.14955.